On October 7, 2021 Locust Walk reported that deal team members compile key statistics and trends on strategic transactions and financings (Press release, Locust Walk Partners, OCT 7, 2021, View Source;utm_medium=rss&utm_campaign=2021-q3-report-global-trends-in-biopharma-transactions [SID1234591035]). Our 2021 Q3 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life sciences deal landscape.
In this report you can find an overview and analysis of the following across the biopharma market in the US, Europe, and Asia (Japan and China):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Key performance indicators for the life science market
IPO and private financing activity and performance
Deal activity for strategic partnership and M&A
A look ahead and our predictions of the future
United States
Biotech indices declined in Q3 2021 (-1.2% NBI, -4.0% BTK), compared to the 0.2% gains of the benchmark S&P 500 this quarter
The US biopharma IPO momentum slowed in Q3 in terms of total aggregate deal value but with slightly higher deal volume compared to Q2
The healthcare SPAC IPO market which began to cool down in Q2 2021 continued its cooling in Q3, with the volume and aggregate deal value of biotech dedicated SPACs falling to near pre-pandemic levels
Despite the apparent slowdown from the previous quarter, public and private financing activity remains strong relative to historical standards
Biopharma companies from the IPO Classes of 2019, 2020, and 2021, on average, all underperformed the major biotech indices this quarter
Strong deal flow among licensing deals demonstrated sustained interest in strategic licensing transactions. Additionally, a dramatic increase in M&A average deal size revealed that the market values clinical-stage biotechnology companies
Europe
The steadily impressive increases in private investment into EU biotech since Q1 2020 has taken a break, raising just over $1B in Q3 2021, a fall of ~35% after the record-setting of ~$1.6B raised in Q2 2021 but still higher than Q3 in 2020 or 2019
Public financings slowed down significantly in Q3 compared to the last two quarters. There were only five small IPOs, all in home exchanges; no biopharmas have crossed the pond this quarter to go public on the US markets
European M&A activity stays consistent in terms of deal volume but total deal value back towards levels seen in Q1 2020
Notably, Q3 EU biopharma licensing agreements surpassed $8.1B in aggregate value, beating the impressive $7.8B of Q2. The deal activity in this quarter was again driven by a strong focus on immuno-oncology, but also by the revival of CNS through three significant deals
Japan
The biotech sector in Q3 2021 fell -13.8% with noticeable drops end of July while the pharma sector stayed flat, and overall growth of the two sectors since the beginning of 2020 is underperforming market
All 5 in-licensing deals in Q3 2021 involved over $200M in deal size, and are split between either phase 3 assets or discovery stage transactions
Following a strong quarter in venture financing in Q2 2021, the trend continues in Q3 which featured 9 deals with aggregate value of $50M; volume and value in 9 months of 2021 already beat the full year record in 2020
China
Average share price of top Chinese pharma dropped by 14.1% due to speculations that the tightening of regulation for IT companies may also happen in the health care sector, while the SSE Composite Index was stable
In-licensing deal volume and value in Q3 2021 outperform Q2 the previous year: 21 in-licensing deals closed including 16 deals with over $50M in total deal size and 15 with over $5M upfront payment
Out-licensing activity was slow in Q3, but with large deal size: RemeGen’s $2.6B deal for ADC program to Seagen
Venture financing for biotech companies continue to exceed previous levels, as 35 companies raised capital for an aggregate total of $2.4B in Q3 alone